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Abstract
The Industrialization Workshop Series aims to promote and discuss integration, automa-
tion, simulation, quality, availability and standards in the high-throughput life sciences.
The main issues addressed being the transformation of bioinformatics and bioinformatics-
based drug design into a robust discipline in industry, the government, research institutes
and academia. The latest workshop emphasized the inﬂuence of the post-genomic era on
medicine and healthcare with reference to advanced biological systems modeling and
simulation, protein structure research, protein-protein interactions, metabolism and
physiology. Speakers included Michael Ashburner, Kenneth Buetow, Francois Cambien,
Cyrus Chothia, Jean Garnier, Francois Iris, Matthias Mann, Maya Natarajan, Peter
Murray-Rust, Richard Mushlin, Barry Robson, David Rubin, Kosta Steliou, John Todd,
Janet Thornton, Pim van der Eijk, Michael Vieth and Richard Ward. Copyright # 2002
John Wiley & Sons, Ltd.
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Introduction
The conference was jointly organized and spon-
sored by the Deep Computing Institute of IBM
(http://www.research.ibm.com/dci/), the Task Force
on Bioinformatics of the International Union of
Pure and Applied Bioinformatics (http://www.iupab.
org/taskforces.html) and the European Bioinfor-
matics Institute (EMBL-EBI, http://www.ebi.ac.uk/).
Barry Robson (IBM Deep Computing Institute)
opened the workshop by stating that industrializa-
tion does not mean commercialization but high-
throughput industrial strength. Last year saw the
development of ‘clinical bioinformatics’ linking cli-
nical data to genomics, requiring a large collective
database that is ‘patient-centric’. This ﬁeld will lead
to improved diagnostic tools, therapeutics and
patient care.
Keynote speakers
Franc ¸ois Cambien (Institut National de la Sante ´e td e
la Recherche Me ´dicale, INSERM) presented his
latest results [9] and gave an overview on the mole-
cular and epidemiological genetics of cardiovascular
disease and the different approaches towards geno-
typing. He stressed the importance of creating a
catalogue of ‘all’ common polymorphisms in the
human genome. Since the start of the Etude Cas-
Te ´moin sur l’Infarctus du Myocarde (ECTIM) in
1988 (the ﬁrst large scale study on myocardial in-
farction, recent ﬁgures on the total number of candi-
date genes and polymorphisms across 29 studies are
now at 102 and 475 respectively as recorded by
GeneCanvas (www.genecanvas.org) a website sup-
ported by INSERM. The project and others will
continue to search for more polymorphisms but
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Copyright # 2002 John Wiley & Sons, Ltd.how many are there, are they all relevant, and how
do we make the most out of this information? Little
is known about the distribution and structure of
polymorphisms across the genome despite the avail-
ability of the almost complete sequence. On the
assumption that there are 10–20 common poly-
morphisms per gene affecting coding and regulatory
regions and that there are around 30 000 human
genes in total, it is estimated that there may be
around 500 000 functionally related SNPs. The classi-
ﬁcation and exploitation of polymorphisms for the
whole genome not only requires data quality,
storage, integration and accessibility, but also an
understanding of data relevance and representation
in relation to complex disorders. Lopez and Murray
[5] ranked cardiovascular disease the ﬁfth most
common disease in 1990 but they estimate that in
2020, it will be the most common disease world-
wide. There is a complex interplay between envir-
onmental and genetic determinants: the former may
explain the difference in disease prevalence between
population groups, and time related changes, while
the latter plays a role in susceptibility. However, the
expectations of ﬁnding genetic factors for multi-
factorial diseases may not be fulﬁlled because many
genes are involved and several models (such as the
whole genome approach) may be much too simplis-
tic. Important correlations may also be found not
only in phenotypes such as clinical data but also in
biological systems. When integrated with epidemiol-
ogy and Mendelian genetics, the application of high
throughput proteomic tools as well as comparative
investigations of different species will provide a
greater understanding into evolution and functional
biology and is expected to provide new leads for
drug development or other approaches to maintain
health.
Janet Thornton (EMBL-EBI, http://www.ebi.ac.
uk/Thornton/index.html) presented results on the
analysis of the domain structure of enzymes and
how this knowledge can be interpreted in the con-
text of the evolution of metabolic pathways [10,8,6].
The results from an analysis of small molecule meta-
bolic pathways in yeast support a ‘mosaic’ model of
evolution in which enzymes in metabolic pathways
are chosen in an unsystematic way to meet the func-
tional requirements of a metabolic pathway. Further
analysis on the conservation of function across
families of homologous enzymes shows that the
degree of functional similarity varies according to the
degree of sequence identity shared by enzyme homo-
logue pairs. High sequence identity corresponds to
almost identical function, while proteins with less
than 30% sequence identity show signiﬁcant func-
tional differences. These results have been applied
to the problem of genome annotation and func-
tional assignments have been catalogued in the
database, Gene3D (http://www.biochem.ucl.ac.uk/
bsm/cath_new/Gene3D/) for a number of completed
genomes, providing functional and structural anno-
tation.
Virtual human biology
Michael Ashburner (University of Cambridge) spoke
about recent developments and tools associated
with the Gene Ontology
2 Consortium (GO, http://
www.geneontology.org/). GO uses a natural lan-
guage ontology system and aims to provide a set
of structured vocabularies for speciﬁc biological
domains that can be used to describe gene products
in any organism. There are GO terms for human,
mouse, rat, worm, ﬂy, amoeba, yeast, Arabidopsis
and the more recently sequenced rice, and TIGR
are now remodeling all their bacterial genomes. The
three organizing principles (orthogonal ontologies)
of GO are: biological process, molecular function
and cellular component. There is a hierarchical
structure within these groups that allows querying
at different levels and as the number of these
parent-child relationships increase, the annotations
get more complex. Many databases are now colla-
borating with GO and these include MGI, LOCUS-
LINK, SWISSPROT and CGAP. Recent browsers
and query tools attached to GO include the follow-
ing: the MGI GO Browser, AmiGO (Berkeley,
http://www.godatabase.org/) ; the CGAP GO Brow-
ser (http://cgap.nci.nih.gov/Genes/GOBrowser), the
EP:GO Browser (http://ep.ebi.ac.uk/EP/GO/)w h i c h
is built into EBI’s Expression Proﬁler (a set of tools
for clustering and analysing microarray data); Quick-
GO (http://www.ebi.ac.uk/ego/) which is integrated
into InterPro; and DAG-Edit (http://sourceforge.
net/projects/geneontology), a purpose built, down-
loadable Java application to maintain, edit and
display GO terms. With the emerging development
of ontologies in other domains, the Global Open
Biology Ontologies (GoBo) or Extended GO
(EGO) has also been set up with the aim of
being open source and DAG-Edit compatible,
using non-overlapping deﬁned terms and common
ID space.
Richard Ward (Oak Ridge National Laboratory)
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(http://www.ornl.gov/virtualhuman/), a human simu-
lation tool. The ambitious goal of the VH will be an
integrated digital representation of the functioning
human from the molecular level to the living
human, and from conception to old age. Tools are
being developed to represent the body’s processes
from DNA molecules and proteins to cells, tissues,
organs and gross anatomy. These tools include
XML (Extensible Markup Language) where ontol-
ogies and a high level description of the human
body are important, visualization tools and prob-
lem solving environments. A forum has been estab-
lished for the digital human effort to provide open
source code tools to represent the body’s processes:
http://www.fas.org/dh/. The Physiome project (http://
www.physiome.org) is another comprehensive mod-
eling environment that aims to promote modeling
for analysing integrative physiological function in
terms of underlying structure and molecular mech-
anisms. There is a recognised need to adopt
standards for data deﬁnition, storage and transfer,
XML to replace standard data input, and databases
for creating and developing XML schemas. There is
also a need to establish integrative databases deal-
ing with genomic, biophysiological, bioengineering
and clinical data. XML descriptions are now becom-
ing more common and examples of these include:
cellular function, cellMEL (http://www.cellml.org); sys-
tems biology modeling, SBML (http://xml.coverpages.
org/sbml.html); and their own prototype for physio-
logical modeling, physioML (http://www.ornl.gov/
virtualhuman). His group originally used a Java
SAX parser for physioML but they converted to
using a Java document object model instead, since
new objects in the description are easily deﬁned and
it allows the integration of physiology and anat-
omy. However, ontologies have an advantage over
XML because they provide a richer description of
relationships (semantic rules) between objects and
interoperability improves between systems. They
are now creating a Digital Human (DH) for the
development of an anatomical ontology. The DH
requires a problem-solving environment for com-
plex 3D-ﬂow modeling and for high performance
computing, three-tiered client/server architecture
with Java RMI and NetSolve (http://icl.cs.utk.edu/
netsolve) is used. He also mentioned how a common
component architecture, which is currently used for
climate modeling, is the way of the future for the
VH project.
Protein structure and protein
interaction
Jean Garnier (INRA – de Recherche de Versailles)
gave an overview of protein structure prediction
techniques, describing some of the more widely used
tools. Structure prediction tools fall into three
classes, those which predict structures from ﬁrst
principles such as molecular dynamics simulations,
those based on statistical analysis, such as hidden
Markov models (HMMs) and those based on
comparison to known structures, i.e. homology
modeling. Jean Garnier stressed the importance of
testing different techniques, referring to EVA and
CASP. EVA is an automatic evaluation tool that
continuously tests publicly available structure pre-
diction servers by feeding them sequences for
known new structures from PDB and comparing
the results with the determined structures. CASP is
a public competition in which experts attempt to
predict structures for proteins whose structures
have been determined but whose structures have
not been made public. So far, structure prediction is
most successful for proteins with known folds.
Identiﬁcation of proteins whose structure may be
similar to a novel protein is often difﬁcult and
attempts to identify homologues of a new sequence
often fail despite the existence of homologues with
known structures because linear alignment of sequ-
ences is not as conserved as a three-dimensional
topology. Some recent ‘threading’ programs have
been developed with better sensitivity than conven-
tional alignment techniques for detecting distant
homologues for novel sequences, such as FORESST
(http://abs.cit.nih.gov/foresst/, 3) and FROST (http://
www.inra.fr/bia/produits/logiciels/BD2html.php?nom=
FROST). The former program predicts which
known fold best matches a novel sequence using
HMMs based on patterns of secondary structure in
proteins with known structures to analyse novel
proteins. Secondary structure prediction algorithms
are applied to the novel sequence to determine a
predicted secondary structure topology which is
then fed to the HMM to identify known structures
with matching topologies.
Major evolutionary transitions have arisen as a
result of changes in protein repertoires and changes
in the expression of protein repertoires. Cyrus
Chothia and Bernard de Bono (at the MRC
Laboratory of Molecular Biology) have been study-
ing the immunoglobulin superfamily as a model of
whole genome protein repertoires. In his talk Dr
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analyses of Ensembl in the context of attempts
to determine the complete repertoire of immuno-
globulin superfamily proteins in the human genome.
Application of HMMs to predicted proteins from
Ensembl to identify immunoglobulin superfamily
proteins is hampered by various issues. Parts of
some genes are absent while parts of other genes are
split and widely separated from each other. Con-
sistency between releases of Ensembl is also a pro-
blem. Each new Ensembl release contains new
protein predictions, while predictions from previous
releases may be deleted. The solution involved
looking at all nine releases of Ensembl to collec-
tively identify all immunoglobulin superfamily pro-
teins from all the predicted proteins in these releases
using HMMs. This was followed by removing
redundant predictions and conﬁrming the quality
of the predictions that remain using GeneWise.
Environmental healthcare issues and
bioinformatics/individuality and the
pursuit of personalised molecular
medicine
Kenneth Buetow (NCBI) is actively involved in the
Cancer Genome Anatomy Project (CGAP) and
spoke about how combining bioinformatics and
genomics gives an insight into the etiology of can-
cer. The most obvious challenges associated with
utilizing large data collections are management,
visualisation and interpretation. If bioinformatics is
to succeed in integrating knowledge from diverse
ﬁelds of research, the problem of standardizing
terminology and language must be overcome. He
discussed how the NCBI is using the GO
2 infra-
structure in cancer research.
The annotation of genomes requires sensitive
tools for the identiﬁcation of homologous proteins,
allowing proteins of unknown function to be linked
to homologues with known function. Conventional
sequence alignment tools are often insensitive to
distant sequence relationships even though the dis-
tantly related sequences may have similar structures
and functions. Since structure is typically more
conserved than sequence, the use of structure based
homologue recognition tools for genome annota-
tion has signiﬁcant value. Michael Sternberg (Imper-
ial College) presented the latest results from his
group on the development of genome annotation
tools based on structural proﬁles [2,7]. His group
has developed tools both to identify distantly
related homologues and to assign function to those
homologues. The 3D-PSSM tool (http://www.sbg.
bio.ic.ac.uk/y3dpssm/) was developed to improve
PSI-BLAST predictions and to detect distant sequ-
ence relationships using structural proﬁles from
known proteins. An algorithm has also been devel-
oped for predicting functional sites in proteins
based on multiple sequence alignment of homolo-
gous sequences followed by identiﬁcation of invar-
iant polar residues. Spatially clustered groups of
these residues are considered to be functional sites.
Comparison of data for proteins with known func-
tional sites with the multiple alignment predictions
showed the system to be 94% accurate. He empha-
sized the extent to which automated methods can be
used but also how human insight can provide added
value to genome annotation projects.
It is proving difﬁcult to develop novel therapeutic
molecules for treatment of multifactorial disorders
based upon known targets despite a steady increase
in the number of such targets. In most cases, thera-
peutic molecules, which successfully alleviate a dis-
ease do not directly affect the causative gene
products, instead they act on the physiological
mechanisms that are ultimately triggered. There-
fore, there is a need to identify these physiological
mechanisms and an understanding of the under-
lying events should be the main aim of the research.
However, technological and conceptual difﬁculties
must be resolved for functionally targeted drug
development to be a reality. Since it is well
established that physiological changes result from
and induce gene expression pattern changes, the
latter together with pathological states could be
used to determine the physiological mechanisms
implicated. However, it is important to consider the
isoforms and any protein modiﬁcations involved,
the types of complexes they associate with and the
nature of the systemic environment. Franc ¸ois Iris
(HemispherxBiopharmaEurope) presentedBio-Graph,
a computer-assisted approach to the determination
of phenotype-speciﬁc physiological mechanisms for
drug discovery. He pointed out the data mining
problems of ‘textual informatics’ and discussed how
to approach them. Biograph is an integrative sys-
tematic approach that is a four-phased physiolo-
gical modeling process. It takes information from
diverse forms and formats to create pertinent
knowledge that is directly implemented to tackle
the biological problems being addressed. In the ﬁrst
phase, data from various biological databases (for
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are mapped into a relational graph, and then in the
second phase, the graph is interpreted in the context
of the problem of interest, leading to a sub-graph
that reveals potential pathological links. The third
phase involves the construction of a theoretical phy-
siological model entirely supported by scientiﬁc
literature and ﬁnally, the last phase identiﬁes
pathway-associated potential intervention points and
therapeutic intervention modes. Direct experimental
biological veriﬁcation of the results is then required.
Kosta Steliou (Boston University) gave an over-
view of population history and genomics. Studies
into patient history and genealogy give important
insights into the molecular basis of disease. He des-
cribed how the analysis of the mitochondrial
genome can be used to segregate patients into medi-
cally relevant genetic subgroups. Research has shown
that there are certain mutations in the mitochon-
drial DNA that are associated with diverse diseases
such as cancer, infertility, diabetes, stroke, deafness
and many others (http://www.mitoresearch.org).
There are also associations between the A3243G
mtDNA mutation and neurodegenerative disorders.
Researching and simulating biomolecular
interaction networks and bioinformatics
aspects of intercellular integration
Despite the ease with which SNPs can be identiﬁed,
determining the biological signiﬁcance of SNPs pro-
vides many challenges. In his presentation, John
Todd (University of Cambridge) gave examples from
his work in type I diabetes (TID), and autoimmune
disease. He pointed out that there are two general
mechanisms by which SNPs have their effect, either
by changing the regulation of the gene or by
changing the precise amino acid sequence coded by
the gene. Analysis of the function of SNPs is
complicated by epistasis (which is where the effects
of one SNP may be masked by another). To deal
with epistasis, large sample sizes are required and
Todd suggested that a case study of around 5000
samples is required. This implies that SNP screening
must become an industrial process once SNPs are
recognized in all haplotypes. However, the techno-
logy is still approximately 12-fold out in terms of
cost therefore more cost effective methods are
required. Genetics has to scale up to enable popu-
lation-based studies and he currently has funding
for a case study of 10 000 DNA patient samples
from the UK Paediatric TID registry. The ‘regis-
tries’ provide a diverse range of cases, patient hist-
ory and other relevant clinical data such as reasons
for death. Another challenge in SNP research is in
understanding splicing complexity.
Matthias Mann (University of Southern Denmark
and MDS-Proteomics) presented the latest results
from his collaborative work on high-throughput
mass spectrometric protein complex identiﬁcation
[4]. Libraries of expressed cDNAs encoding ‘bait’
proteins are prepared by a high-throughput recom-
bination procedure such that the members of the
library of expressed proteins are each linked to
an epitope tag. This tag may be used to immuno-
precipitate the expressed ‘bait’ protein and any
proteins that are interacting with the ‘bait’ protein
from whole cell extracts. The components of the
immunoprecipitated complex can then be identiﬁed
further by gel electrophoresis and peptide mass
ﬁngerprinting. The technique found 3-times more
interactions than the yeast 2-hybrid technology in a
comprehensive study of the yeast proteome. Some
teething troubles were mentioned such as ectopic
expression of the tagged clones and a signiﬁcant
number of false positives. The ﬁltered data set has
been deposited in BIND
2, a powerful protein-
protein interaction database (http://www.bind.ca/).
Raw data can be obtained from http://www.mdsp.
com/yeast.
Matthias Mann also referred to his latest work in
collaboration with Angus Lamond in Dundee on
the characterisation of the nucleolus, a substructure
within the cell nucleus [1]. This project aims to
determine which proteins are found in the nucleo-
lus, what they interact with, and what their function
is. Nucleolar isolation followed by 2-D gel electro-
phoresis and peptide mass ﬁngerprinting has been
used to identify components of the nucleolus. Issues
that have arisen from this project include how to
conﬁrm that proteins identiﬁed by this process
actually reside in the nucleolus rather than being
contaminants. Fluorescence localization using Yellow
Fluorescent Protein tagged clones was carried out
to conﬁrm nucleolar residence of the proteins
identiﬁed by mass spectrometry.
Matthias Mann emphasized the need for stan-
dards to interpret proteomic data particularly given
the variety of analytical methods that are referred
to as proteomic techniques. Predictive tools may
become more valuable for functional pathways once
more data is available, such as more in vivo data on
274 Meeting Review: Bioinformatics and Medicine
Copyright # 2002 John Wiley & Sons, Ltd. Comp Funct Genom 2002; 3: 270–276.phosphorylation sites to allow the identiﬁcation of
unknown proteins with phosphorylation sites.
David Rubin presented Cognia, a company that is
developing proteomic database products. Cognia
has licensed the right to distribute commercial ver-
sions of the TRANSFAC and TRANSPATH data-
bases with improved querying tools and interfaces.
Cognia is also developing a proprietary relational
database product, the Protein Catabolism DataBase
(PCDB), a comprehensive database on protein turn-
over and protein degradation pathways. This will be
of value in a number of diseases in which protein
turnover is believed to be aberrant, such as in cer-
tain cancers, neurodegenerative diseases and inﬂam-
matory disorders. The PCDB database includes
data on degradation mechanisms, post-translational
modiﬁcations, structure, protein-protein interac-
tions and signal transduction. The PCDB product
includes search tools to enable Boolean queries,
structural searching and tools to enable tailored
curation speciﬁc to particular organizations or pro-
jects. The design of the database is amenable to
inclusion of open source code.
Molecular docking is a technique for determining
how well pairs of molecules interact with each
other. Pairs of molecules are ‘docked’ in various
orientations and the energy of each interaction is
scored. The process is repeated to ﬁnd the best
interaction between the pair. Applications include
‘in silico’ drug screening to ﬁlter compound libraries
prior to actual screening and prediction of binding
conformation of hits from screening. Michael Vieth
(Eli Lilly and Company) addressed various limi-
tations of docking algorithms. The ﬂexibility of
proteins, and their ability to adopt novel conforma-
tions on ligand binding, are difﬁcult to account for,
as are changes in ligand conformation. Multiple
X-ray structures and improved Structure Activity
Relationships (SARs) from known proteins/ligand
complexes can improve predictions for new proteins
and/or new ligands.
E-Medicine, medical research and
healthcare in an Internet world
MayaNatarajan (Entropia, Inc., http://www.entropia.
com/) presented results of how ‘grid computing’ aka
‘distributed computing’ can accelerate bioinfor-
matics research. Using BLAST results and results
from docking experiments from a pharmaceutical
company, she demonstrated how moderately sized
networks of PCs that are actively performing
menial tasks can provide signiﬁcant computational
power for processor intensive problems. The com-
putational power derived from such networks grows
linearly with the number of computing nodes within
the network and the use of such networks provides
a cost-effective solution for high performance com-
putational needs.
Barry Robson’s presentation on ‘Health Care and
Personalised Medicine’ was a visionary account of
what the healthcare system might be like in the
future and how this may be achieved. The medicine
of the future will take advantage of personal geno-
mic and expression data but such data cannot be
used to its full potential unless there is an effective
link and accessibility to patient records. IBM’s
vision for a global healthcare system, ‘The Secure
Health and Medical Access Network’ (SHAMAN)
provides the infrastructure for this goal. The future
prospect of designing personal drugs in real time is
achievable. The drugs will be designed for patients
on high performance servers at pharmaceutical
companies and FDA ofﬁces. However, such a
vision will mean that a change in the healthcare
system is required. The development of SHAMAN
essentially requires the encoding of patient record
into digital form and the team is working closely with
a group in Oxford on bioethics issues. An XML
standard is used for the ‘clinical’ document ‘architec-
ture’ and various forms of visualization tools are
being developed. Mitochondrial DNA may be used
as a ‘barcode’ for the record. A major problem is that
the data is dirty, sparse and in a high dimensional
space. Algorithms are required to cope with this, for
example, knowledge can be reduced into a few
terms using mathematical terminologies. Extensions
to SHAMAN will include a database of potential
pathogens and also a database of animal models for
human disease.
Richard Mushlin (IBM T. J. Watson Research
Center) mentioned that digital patient data has been
around for many years now, and the recent success
of these systems is largely due to the diverse forms
of data being structured according to standards and
brought under the control of integrated applica-
tions. Several of these applications are complete
enough such that virtually no paper work is involved.
However, with the emergence of new multi-source
data types such as personal genomic information,
these systems must be able to accommodate them
electronically, or risk returning to paper records. He
emphasized the importance of integrating genomic
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coveries. Re-evaluation tools for the data will be
required as more information is fed to the system.
Pim van der Eijk (Oasis, http://www.oasis-open.
org/) gave a high-level introduction to XML and
presented the results of a survey of several XML-
based languages in biology with the emphasis on
schema design, process issues and XML-based
knowledge formalisms.
Peter Murray-Rust (Unilever Centre for Molecular
Informatics) described an XML based system for
chemical nomenclature. He emphasized the need for
agreed ontologies and discussed the problems of
overlapping domains. Scientiﬁc publication can be
used to create a knowledge base, or semantic web,
and this has great potential in providing novel
knowledge discoveries beyond what is presently
found in traditional publications.
Conclusion
A diverse array of subjects was covered by the
speakers and a number of underlying themes have
emerged relating to the exploitation of genomic
data, principally the need for standardization both
of data structure and vocabulary. To achieve this
goal of integration of disciplines as varied as clinical
genetics, structural genomics and proteomics, this
process of standardization will need to be far-
reaching and extensive, and achieve global accep-
tance. Scientiﬁc publication can also provide and
create a wealth of knowledge, however, publication
will need to be in an accessible format for data
integration and mining. Furthermore, if medical
research is to evolve, academics in particular need
to take an ‘industrial approach’ to research in order
to achieve the necessary scale of data acquisition
and management for genome-wide population based
studies. To successfully scale up, research processes
will require effective automation particularly of
genome annotation and the task of assigning
functions to novel sequences. High throughput
structure analysis is beginning to provide auto-
mated methods of genome annotation. Accurate
functional annotation of genomes will lead to better
interpretation of both molecular and clinical genet-
ics, allowing structural and functional information
to be linked to clinical phenotypes. The ultimate
outcome of this process of integration will be
improved health-care for all.
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